Saturday 17 October 2026
Export ACOG’s income statement to Excel — free account
Alpha Cognition Inc.
ACOG Healthcare Biotechnology
Alpha Cognition Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million. In the quarter to June 2026, revenue grew 267.6%, EPS grew 38.5% and free cash flow fell 109.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.19
0.26
−3.08%
Follow ACOG
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 17.35 | 26.08 | 30.04 | — | — | — | — | — | 4.66 | 3.75 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 26.51 | 28.43 | 30.50 | — | — | — | — | — | 7.00 | 11.54 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 57 | 71 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.14 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 10 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | 81.26 | |||||
| EBT | — | — | — | (7) | (6) | (20) | (12) | (14) | (15) | (21) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (202.24) | |||||
| Net income | — | — | — | (7) | (6) | (20) | (12) | (14) | (15) | (21) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 | ||||
| Earnings | — | — | — | (5.25) | (3.37) | (9.25) | (4.50) | (3.75) | (2.02) | (1.17) | |||||
| Cash flow | — | — | — | (2.03) | (3.17) | (4.63) | (3.40) | (2.45) | (1.07) | (1.15) | |||||
| Capex | — | — | — | 0.00 | (0.01) | (0.03) | 0.00 | 0.00 | 0.00 | (0.02) | |||||
| Free cash flow | — | — | — | (2.03) | (3.17) | (4.66) | (3.40) | (2.45) | (1.07) | (1.17) | |||||
| Book value | — | — | — | 4.17 | 0.01 | 4.23 | (0.49) | (1.31) | 5.39 | 3.54 | |||||
| Shares, m | — | — | — | 1 | 2 | 2 | 3 | 4 | 7 | 18 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 11.24 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 1.84 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 4.87 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (2.40) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (5) | (10) | (9) | (9) | (8) | (20) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | — | 0 | 0 | |||||
| Free cash flow | — | — | — | (3) | (5) | (10) | (9) | (9) | (8) | (21) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 5 | 4 | 10 | (2) | (1) | 47 | 70 | ||||
| Total debt | — | — | — | 1 | 3 | — | — | — | — | — | |||||
| Net debt | — | — | — | (5) | (3) | (11) | (2) | (1) | (49) | (66) | |||||
| Shareholders’ equity | — | — | — | 5 | 0 | 9 | (1) | (5) | 39 | 63 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (78.00) | (183.38) | (153.05) | (509.46) | (55.61) | (31.69) | ||||
| ROIC | — | — | — | (685.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | (219.92) | (432.14) | (314.28) | 456.96 | (86.00) | (40.68) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Alpha Cognition Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics SA | $190.2M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| STRO Sutro Biopharma, Inc. | $190.0M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| YARW Yarrow Bioscience, Inc | $188.8M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| TRDA Entrada Therapeutics, Inc. | $186.1M | — (loss-making) | — (loss-making) | −53.95% (below 0%: shrinking) | n/m | −9.10% (below 0%: shrinking) | 100.00% | (5,007.02%) | Compare |
| UPB Upstream Bio, Inc. | $184.6M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| ELDN Eledon Pharmaceuticals, Inc. | $184.5M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SION Sionna Therapeutics, Inc. | $184.5M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| ACOG Alpha Cognition Inc. | $184.0M | — (loss-making) | — | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $181.4M | — (loss-making) | — (loss-making) | −78.46% (below 0%: shrinking) | n/m | +31.95% (above 0%: growing) | 100.00% | (8,673.93%) | Compare |
| Median of peers | $185.4M | — | — | −35.72% | — | +11.94% | 100.00% | (1,750.85%) |
Alpha Cognition Inc. (ACOG) key facts
- Alpha Cognition Inc. (ACOG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Alpha Cognition Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million.
- As of October 16, 2026, ACOG traded at $8.19, a market capitalization of $184.0 million.
- Return on equity was −40.7% and debt-to-equity 0.00.
- Its Altman Z-score is 2.55 (grey zone) for fiscal 2025.